These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 11172188)

  • 41. CD4 T cell nadir independently predicts the magnitude of the HIV reservoir after prolonged suppressive antiretroviral therapy.
    Boulassel MR; Chomont N; Pai NP; Gilmore N; Sékaly RP; Routy JP
    J Clin Virol; 2012 Jan; 53(1):29-32. PubMed ID: 22019250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The effect of high-dose saquinavir on viral load and CD4+ T-cell counts in HIV-infected patients.
    Schapiro JM; Winters MA; Stewart F; Efron B; Norris J; Kozal MJ; Merigan TC
    Ann Intern Med; 1996 Jun; 124(12):1039-50. PubMed ID: 8633817
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA.
    Gianella S; von Wyl V; Fischer M; Niederoest B; Battegay M; Bernasconi E; Cavassini M; Rauch A; Hirschel B; Vernazza P; Weber R; Joos B; Günthard HF;
    Antivir Ther; 2011; 16(4):535-45. PubMed ID: 21685541
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia.
    Deeks SG; Barbour JD; Grant RM; Martin JN
    AIDS; 2002 Jan; 16(2):201-7. PubMed ID: 11807304
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy?
    Frenkel LM; Mullins JI
    N Engl J Med; 2001 Feb; 344(7):520-2. PubMed ID: 11172196
    [No Abstract]   [Full Text] [Related]  

  • 46. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection.
    Cao Y; Qin L; Zhang L; Safrit J; Ho DD
    N Engl J Med; 1995 Jan; 332(4):201-8. PubMed ID: 7808485
    [TBL] [Abstract][Full Text] [Related]  

  • 47. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.
    Gortmaker SL; Hughes M; Cervia J; Brady M; Johnson GM; Seage GR; Song LY; Dankner WM; Oleske JM;
    N Engl J Med; 2001 Nov; 345(21):1522-8. PubMed ID: 11794218
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.
    Dyrhol-Riise AM; Voltersvik P; Berg OG; Olofsson J; Kleivbo S; Asjö B
    AIDS Res Hum Retroviruses; 2001 May; 17(7):577-86. PubMed ID: 11375053
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patterns of plasma human immunodeficiency virus type 1 RNA response to highly active antiretroviral therapy in infected children.
    Spector SA; Hsia K; Yong FH; Cabral S; Fenton T; Fletcher CV; McNamara J; Mofenson LM; Starr SE
    J Infect Dis; 2000 Dec; 182(6):1769-73. PubMed ID: 11069252
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Persistence of human immunodeficiency virus (HIV) type 1 DNA in peripheral blood despite prolonged suppression of plasma HIV-1 RNA in children.
    Saitoh A; Hsia K; Fenton T; Powell CA; Christopherson C; Fletcher CV; Starr SE; Spector SA
    J Infect Dis; 2002 May; 185(10):1409-16. PubMed ID: 11992275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in human immunodeficiency virus-specific cellular immunity.
    Price DA; Scullard G; Oxenius A; Braganza R; Beddows SA; Kazmi S; Clarke JR; Johnson GE; Weber JN; Phillips RE
    J Virol; 2003 May; 77(10):6041-9. PubMed ID: 12719595
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy.
    Cassol E; Malfeld S; Mahasha P; van der Merwe S; Cassol S; Seebregts C; Alfano M; Poli G; Rossouw T
    J Infect Dis; 2010 Sep; 202(5):723-33. PubMed ID: 20629534
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Drug resistance among drug-naive and first-line antiretroviral treatment-failing children in Cameroon.
    Fokam J; Salpini R; Santoro MM; Cento V; Perno CF; Colizzi V; Ndumbe PM; Fokunang Ntungen C; Ndiang Tetang SM; Nanfack AJ; Takou Komego DA; Cappelli G
    Pediatr Infect Dis J; 2011 Dec; 30(12):1062-8. PubMed ID: 21817951
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS.
    Baxter JD; Mayers DL; Wentworth DN; Neaton JD; Hoover ML; Winters MA; Mannheimer SB; Thompson MA; Abrams DI; Brizz BJ; Ioannidis JP; Merigan TC
    AIDS; 2000 Jun; 14(9):F83-93. PubMed ID: 10894268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.
    Stanley SK; Ostrowski MA; Justement JS; Gantt K; Hedayati S; Mannix M; Roche K; Schwartzentruber DJ; Fox CH; Fauci AS
    N Engl J Med; 1996 May; 334(19):1222-30. PubMed ID: 8606717
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mechanism of HIV antiretroviral drugs progress toward drug resistance.
    Ammaranond P; Sanguansittianan S
    Fundam Clin Pharmacol; 2012 Feb; 26(1):146-61. PubMed ID: 22118474
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The independent effect of drug resistance on T cell activation in HIV infection.
    Hunt PW; Deeks SG; Bangsberg DR; Moss A; Sinclair E; Liegler T; Bates M; Tsao G; Lampiris H; Hoh R; Martin JN
    AIDS; 2006 Mar; 20(5):691-9. PubMed ID: 16514299
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Low-level viremia in HIV-1 infection: consequences and implications for switching to a new regimen.
    Cohen C
    HIV Clin Trials; 2009; 10(2):116-24. PubMed ID: 19487182
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Temporal change in the use of genotypic resistance testing over the years 1999--2003.
    Santoro M; Ceccherini-Silberstein F; Gori C; Svicher V; Forbici F; Bellocchi MC; d'Arrigo R; Bertoli A; Giannella S; Trotta MP; Bonfigli S; Antinori A; Perno CF
    New Microbiol; 2004 Apr; 27(2 Suppl 1):141-4. PubMed ID: 15646078
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.